Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia
Open Access
- 1 January 2011
- journal article
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 3 (1), 60-63
- https://doi.org/10.1159/000324344
Abstract
Psoriasis is a chronic immunologically-based inflammatory skin disease. B-chronic lymphocytic leukemia (B-CLL) is a form of leukemia characterized by the slow and progressive accumulation of monoclonal CD5+ B lymphocytes in peripheral blood, bone marrow, lymph nodes and other organs. A T-helper 1 cytokine-mediated pathway is involved in these disorders in which tumor necrosis factor-α (TNF-α) plays a central role. TNF-α is involved in physiological phenomena, such as host defense, inflammation and cell differentiation, and in many pathological conditions, such as fever and some malignant neoplasms. TNF-α involvement in psoriasis has been well validated by the clinical success of anti-TNF-α therapy. TNF-α has been well studied in the pathogenesis of B-CLL, suggesting it as a target in B-CLL therapy. We present the case of a patient suffering from plaque psoriasis and B-CLL. Since TNF-α is reported as a common link between psoriasis and B-CLL, the patient was treated with etanercept followed by infliximab, two anti-TNF-α drugs. During 3 years of therapy, the patient did not show significant modifications of lymphocyte levels, indicating no progression of B-CLL. We report this case to highlight the possibility to administer anti-TNF-α treatment in psoriatic patients affected by concomitant B-CLL.Keywords
This publication has 12 references indexed in Scilit:
- TNFα and its Receptors in Psoriatic Skin, before and after Treatment with EtanerceptInternational Journal of Immunopathology and Pharmacology, 2009
- PsoriasisThe New England Journal of Medicine, 2009
- Polymorphisms of tumor-necrosis factor-α−308 and lymphotoxin-α + 250: Possible modulation of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononuclear cellsLeukemia & Lymphoma, 2008
- Immunopathogenesis of psoriasisExperimental Dermatology, 2007
- B-chronic lymphocytic leukemia cells exert an in vitro cytotoxicity mediated by tumor necrosis factor αLeukemia Research, 2005
- Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL.Current Drug Targets - Cardiovascular & Hematological Disorders, 2003
- Production of intracellular IL-2, TNF-α, and IFN-γ by T cells in B-CLLCytometry Part B: Clinical Cytometry, 2003
- TNF-Related Ligands and Their ReceptorsCellular Signalling, 1998
- Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 1995
- Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomasBlood, 1995